NCT01947140 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Cohort 1, Dose Level -1 Subjects will be administered through IV: Pralatrexate 10 mg/m2 on days 1 and 8 of each 21 day cycle. Romidepsin 12 mg/m2 on days 1 and 8 of each 21 day cycle.
- id
- FG000
- title
- Pralatrexate 10 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 2A, Dose Level 1 Subjects will be administered through IV: Pralatrexate 15 mg/m2 on days 1 and 8 of each 21 day cycle. Romidepsin 12 mg/m2 on days 1 and 8 of each 21 day cycle.
- id
- FG001
- title
- Phase 1 Schedule A: Pralatrexate 15 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 2B, Dose Level 1 Subjects will be administered through IV: Pralatrexate 15 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG002
- title
- Phase 1 Schedule B: Pralatrexate 15 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 3A, Dose Level 2 Subjects will be administered through IV: Pralatrexate 15 mg/m2 on days 1 and 8 of each 21 day cycle. Romidepsin 14 mg/m2 on days 1 and 8 of each 21 day cycle.
- id
- FG003
- title
- Phase 1 Schedule A: Pralatrexate 15 mg/m2, Romidepsin 14 mg/m2
- description
- Cohort 3B, Dose Level 2 Subjects will be administered through IV: Pralatrexate 15 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 14 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG004
- title
- Phase 1 Schedule B: Pralatrexate 15 mg/m2, Romidepsin 14 mg/m2
- description
- Cohort 4A, Dose Level 3 Subjects will be administered through IV: Pralatrexate 20 mg/m2 on days 1 and 8 of each 21 day cycle. Romidepsin 12 mg/m2 on days 1 and 8 of each 21 day cycle.
- id
- FG005
- title
- Phase 1 Schedule A: Pralatrexate 20 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 4B, Dose Level 3 Subjects will be administered through IV: Pralatrexate 20 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG006
- title
- Phase 1 Schedule B: Pralatrexate 20 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 5B, Dose Level 4 Subjects will be administered through IV: Pralatrexate 25 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG007
- title
- Phase 1 Schedule B: Pralatrexate 25 mg/m2, Romidepsin 12 mg/m2
- description
- Subjects will be administered through IV: Pralatrexate 25 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG008
- title
- Phase 2: Pralatrexate 25 mg/m2, Romidepsin 12 mg/m2
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohort 1: Dose Level -1
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohorts 2A and 2B: Dose Level 1
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohorts 3A & 3B: Dose Level 2
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohorts 4A and 4B: Dose Level 3
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 6
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 6
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohort 5B: Dose Level 4
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 18
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 18
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Phase 2
Complete source fields
- groups
- description
- Cohort 1, Dose Level -1 Subjects will be administered through IV: Pralatrexate 10 mg/m2 on days 1 and 8 of each 21 day cycle. Romidepsin 12 mg/m2 on days 1 and 8 of each 21 day cycle.
- id
- FG000
- title
- Pralatrexate 10 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 2A, Dose Level 1 Subjects will be administered through IV: Pralatrexate 15 mg/m2 on days 1 and 8 of each 21 day cycle. Romidepsin 12 mg/m2 on days 1 and 8 of each 21 day cycle.
- id
- FG001
- title
- Phase 1 Schedule A: Pralatrexate 15 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 2B, Dose Level 1 Subjects will be administered through IV: Pralatrexate 15 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG002
- title
- Phase 1 Schedule B: Pralatrexate 15 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 3A, Dose Level 2 Subjects will be administered through IV: Pralatrexate 15 mg/m2 on days 1 and 8 of each 21 day cycle. Romidepsin 14 mg/m2 on days 1 and 8 of each 21 day cycle.
- id
- FG003
- title
- Phase 1 Schedule A: Pralatrexate 15 mg/m2, Romidepsin 14 mg/m2
- description
- Cohort 3B, Dose Level 2 Subjects will be administered through IV: Pralatrexate 15 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 14 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG004
- title
- Phase 1 Schedule B: Pralatrexate 15 mg/m2, Romidepsin 14 mg/m2
- description
- Cohort 4A, Dose Level 3 Subjects will be administered through IV: Pralatrexate 20 mg/m2 on days 1 and 8 of each 21 day cycle. Romidepsin 12 mg/m2 on days 1 and 8 of each 21 day cycle.
- id
- FG005
- title
- Phase 1 Schedule A: Pralatrexate 20 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 4B, Dose Level 3 Subjects will be administered through IV: Pralatrexate 20 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG006
- title
- Phase 1 Schedule B: Pralatrexate 20 mg/m2, Romidepsin 12 mg/m2
- description
- Cohort 5B, Dose Level 4 Subjects will be administered through IV: Pralatrexate 25 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG007
- title
- Phase 1 Schedule B: Pralatrexate 25 mg/m2, Romidepsin 12 mg/m2
- description
- Subjects will be administered through IV: Pralatrexate 25 mg/m2 on days 1 and 15 of each 28 day cycle. Romidepsin 12 mg/m2 on days 1 and 15 of each 28 day cycle.
- id
- FG008
- title
- Phase 2: Pralatrexate 25 mg/m2, Romidepsin 12 mg/m2
- periods
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 3
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohort 1: Dose Level -1
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 3
- group Id
- FG002
- num Subjects
- 3
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohorts 2A and 2B: Dose Level 1
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 3
- group Id
- FG004
- num Subjects
- 3
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohorts 3A & 3B: Dose Level 2
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 5
- group Id
- FG006
- num Subjects
- 3
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohorts 4A and 4B: Dose Level 3
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 6
- group Id
- FG008
- num Subjects
- 0
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 6
- group Id
- FG008
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Cohort 5B: Dose Level 4
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 18
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 18
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 0
- group Id
- FG001
- num Subjects
- 0
- group Id
- FG002
- num Subjects
- 0
- group Id
- FG003
- num Subjects
- 0
- group Id
- FG004
- num Subjects
- 0
- group Id
- FG005
- num Subjects
- 0
- group Id
- FG006
- num Subjects
- 0
- group Id
- FG007
- num Subjects
- 0
- group Id
- FG008
- num Subjects
- 0
- type
- NOT COMPLETED
- title
- Phase 2
Download exact source JSON → · Snapshot ctgov-results-d643ffaf417bcef6d45eb5e0
Preserved source evidence · Not medical advice
Triangle